Lyra Therapeutics LYRA 深 沪
等待开盘 11-03 09:30:00 美东时间
5.76
+0.240
+4.35%
华盛通- 最 高5.85
- 今 开5.53
- 成交量 1.37万股
- 最 低 5.53
- 昨 收 5.52
- 总市值 947.23万
- 52周最高 37.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.10
- 委 比 33.33%
- 总股本 164.45万
- 历史最高 1100.00
- 量 比 0.63
- 振 幅 5.80%
- 历史最低 4.10
- 每 手 1
- 风险率 3.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Lyra Therapeutics Outlines Clinical Plan For LYR-210 Following FDA Meeting And Announces ENLIGHTEN 2 Late-Breaking Oral Presentation
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting
10-06 19:08
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
09-03 00:33
Lyra Therapeutics Receives Nasdaq Deficiency Letter
An update from Lyra Therapeutics ( ($LYRA) ) is now available. On August 20, 20...
08-23 04:53
Lyra Therapeutics Q2 EPS $(5.51) Beats $(6.02) Estimate, Sales $183.000K Beat $171.250K Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(5.51) per share which beat the analyst consensus estimate of $(6.02) by 8.47 percent. This is a 85.01 percent increase over losses of $(36.76) per share from
08-13 04:19
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics announced strong Phase 3 results for LYR-210 in chronic rhinosinusitis (CRS), enabling business momentum and securing $5 million financing extending cash runway into Q3 2026. The ENLIGHTEN 2 trial met primary and secondary endpoints, with LYR-210 showing significant symptom improvement and safety. The company resumed manufacturing, engaged FDA discussions, and adjusted stock split to regain compliance. Second-quarter financials ...
08-12 20:01
Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (NASDAQ:LYRA) registers 846,744 shares of common stock for resale by selling securityholders. Shares are issuable upon exercise of outstanding warrants; company will receive proceeds...
07-23 05:46
Lyra Therapeutics Secures $4.3M in Direct Offering
Lyra Therapeutics ( ($LYRA) ) just unveiled an update. On June 26, 2025, Lyra T...
06-27 22:59
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Lyra Therapeutics announced a registered direct offering of 423,372 common shares priced at $11.81 each, along with a concurrent private placement of warrants for up to 846,744 shares with an exercise price of $11.56. The initial gross proceeds are $5.0 million, with the potential for an additional $9.8 million from warrant exercises. Proceeds will be used for working capital, clinical development, and pre-commercialization of LYR-210. The offeri...
06-27 12:00
